个体化与标准化认知行为疗法对癌症幸存者恐惧复发、抑郁或疲乏的随机对照试验方案
本研究为多中心、非盲、双臂(1:1)随机对照试验,比较系统性个体化认知行为疗法与标准化认知行为疗法在癌症幸存者中的疗效。研究对象为存在中重度恐惧复发、抑郁症状和/或癌因性疲乏且完成根治性治疗至少6个月至最多5年的癌症幸存者,共190例。主要结局为日常功能受限,次要结局包括恐惧复发水平、抑郁症状、疲乏严重度、生活质量、目标达成、治疗师时间和脱落率,随访至12个月。
要点
- 首个比较个体化与标准化认知行为疗法在癌症幸存者中疗效的随机对照试验。
- 个体化从治疗模块分配、治疗实施、患者需求及治疗时长四个维度进行。
- 主要结局为日常功能受限,随访6个月和12个月评估。
核心结论
- 旨在验证系统性个体化认知行为疗法是否优于标准化认知行为疗法,改善癌症幸存者的日常功能受限。
研究设计与样本
- 多中心、非盲、双臂(1:1)随机对照试验,计划纳入190例癌症幸存者。
- 纳入标准:存在中重度恐惧复发、抑郁症状和/或癌因性疲乏,且完成根治性治疗至少6个月至最多5年。
关键数值与推荐
- 个体化维度包括:基于生态瞬时评估分配治疗模块、治疗实施方式、患者对症状的需求、治疗时长。
- 主要结局为日常功能受限;次要结局包括恐惧复发水平、抑郁症状、疲乏严重度、生活质量、目标达成、治疗师时间、脱落率。
- 评估时间点为基线(T0)、6个月(T1)和12个月(T2)。
临床怎么用
- 若证实有效,可为癌症幸存者中恐惧复发、抑郁或疲乏的个体化认知行为治疗提供循证框架。
局限性
- 研究方案阶段,尚未报告疗效数据;为非盲设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fear of cancer recurrence, depressive symptoms, and cancer-related fatigue are prevalent symptoms among cancer survivors, adversely affecting patients' quality of life and daily functioning. Effect sizes of interventions targeting these symptoms are mostly small to medium. Personalizing treatment is assumed to improve efficacy. However, thus far the empirical support for this approach is lacking. The aim of this study is to investigate if systematically personalized cognitive behavioral therapy is more efficacious than standard cognitive behavioral therapy in cancer survivors with moderate to severe fear of cancer recurrence, depressive symptoms, and/or cancer-related fatigue. METHODS: The study is designed as a non-blinded, multicenter randomized controlled trial with two treatment arms (ratio 1:1): (a) systematically personalized cognitive behavioral therapy and (b) standard cognitive behavioral therapy. In the standard treatment arm, patients receive an evidence-based diagnosis-specific treatment protocol for fear of cancer recurrence, depressive symptoms, or cancer-related fatigue. In the second arm, treatment is personalized on four dimensions: (a) the allocation of treatment modules based on ecological momentary assessments, (b) treatment delivery, (c) patients' needs regarding the symptom for which they want to receive treatment, and (d) treatment duration. In total, 190 cancer survivors who experience one or more of the targeted symptoms and ended their medical treatment with curative intent at least 6 months to a maximum of 5 years ago will be included. Primary outcome is limitations in daily functioning. Secondary outcomes are level of fear of cancer recurrence, depressive symptoms, fatigue severity, quality of life, goal attainment, therapist time, and drop-out rates. Participants are assessed at baseline (T0), and after 6 months (T1) and 12 months (T2). DISCUSSION: To our knowledge, this is the first randomized controlled trial comparing the efficacy of personalized cognitive behavioral therapy to standard cognitive behavioral therapy in cancer survivors. The study has several innovative characteristics, among which is the personalization of interventions on several dimensions. If proven effective, the results of this study provide a first step in developing an evidence-based framework for personalizing therapies in a systematic and replicable way. TRIAL REGISTRATION: The Dutch Trial Register (NTR) NL7481 (NTR7723). Registered on 24 January 2019.
引用
- Harnas SJ, Knoop H, Bennebroek Evertsz F, et al. Personalized versus standard cognitive behavioral therapy for fear of cancer recurrence, depressive symptoms or cancer-related fatigue in cancer survivors: study protocol of a randomized controlled trial (MATCH-study). Trials. 2021. PMID: 34641961. doi:10.1186/s13063-021-05657-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。